Source: International Congress 2017 – Rare diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Ugur Chousein (ISTANBUL, Turkey). The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?. 1519

Member's Comments

No comment yet.

Related content which might interest you: Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Is there any clinical application for determining the serum cytokines profile in sarcoid patients? Source: Annual Congress 2008 - Clinical aspects in the management of sarcoidosis Year: 2008 Serum C-reactive protein concentrations in patients with sarcoidosis: can be taken this simple test as an activation marker in sarcoidosis? Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Serum biomarkers in SSc-ILD: association with presence, severity and prognosis Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Visfatin as a possible serum biomarker in COPD Source: International Congress 2019 – Crosstalk in chronic pulmonary diseases Year: 2019 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Circulating total leptin as a diagnostic and prognostic biomarker in sepsis Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 Serum amyloid A as a potential biomarker of sarcoidosis Source: Annual Congress 2011 - Lung development and neoplasia Year: 2011 Sarcoidosis: serum and imaging biomarkers Source: Eur Respir Monogr 2022; 96: 107-121 Year: 2022 Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Serum KL-6 and SP-D as useful clinical indicators of interstitial changes and pulmonary functional abnormality in patients with Sjogren's syndrome Source: Eur Respir J 2001; 18: Suppl. 33, 367s Year: 2001 Evaluation of CCL18 serum levels and genetic variant as prognostic biomarkers in SSc-ILD Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 KL-6 is a useful serum biomarker for early detection of interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities Year: 2012 Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020 The diagnostic value of serum soluble CD 14 and IL-10 levels in newly diagnosed pulmonary tuberculosis patients and the relationship with disease extensity Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 The effect of exercise on serum amyloid a levels in patients with sarcoidosis: A preliminary report Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Serum CC16 is a potential predictor for IPF diagnosis and prognosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020